Racial Disparities in Presentation, Diagnosis, and Treatment of MM
Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.
EP: 1.Frontline Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 2.Comparison of Results from the MAIA and SWOG0777 Studies
EP: 3.Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence
EP: 4.Treatment Decision-Making Based on Real-World Data in Transplant-Ineligible NDMM
EP: 5.Maintenance Therapy in Transplant-Ineligible Multiple Myeloma
EP: 6.Determining Treatment Duration for Transplant-Ineligible Multiple Myeloma
EP: 7.Unmet Needs of Transplant-Ineligible Multiple Myeloma
EP: 8.Racial Disparities in the Treatment of Multiple Myeloma Patients
EP: 9.Comparing Combination Treatment Regimens in Transplant-Eligible NDMM
EP: 10.Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?
EP: 11.The GMMG HD7 Trial of Isa-VRd vs VRd in Transplant-Eligible NDMM
EP: 12.Treatment Decision-Making Based on Clinical Trial Data in Transplant-Eligible NDMM
EP: 13.Treatment Decision-Making Based on Real-World Data in Transplant-Eligible NDMM
EP: 14.Measuring Treatment Response in Transplant-Eligible NDMM after Induction Therapy
EP: 15.Recap: Recent Advances in Multiple Myeloma: Applying Real-world Evidence to Clinical Practice
EP: 16.Determining Treatment Duration for Transplant-Eligible NDMM
Now Viewing
EP: 17.Racial Disparities in Presentation, Diagnosis, and Treatment of MM
EP: 18.Unmet Needs and Future Perspectives in Transplant-Eligible NDMM
EP: 19.Characterization and Management of High-Risk Patients with MM
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
